Figure 2
Figure 2. Survival for the entire study population categorized by immunophenotype per WHO classification. (A) Event-free survival and (B) overall survival of patients with T-ALL/LBL (n = 111) categorized as early, thymic, and mature per WHO classification. NR, not reached.

Survival for the entire study population categorized by immunophenotype per WHO classification. (A) Event-free survival and (B) overall survival of patients with T-ALL/LBL (n = 111) categorized as early, thymic, and mature per WHO classification. NR, not reached.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal